卡瑞利珠单抗致声音嘶哑1例
Dysphonia induced by camrelizumab:one case report
王永宽 1黄妮娅 2李寅珊 2马玲2
作者信息
- 1. 云南省第一人民医院,昆明理工大学附属医院临床药学,云南昆明 650032;曲靖市会泽县人民医院药剂科,云南曲靖 654200
- 2. 云南省第一人民医院,昆明理工大学附属医院临床药学,云南昆明 650032
- 折叠
摘要
67岁男性肝恶性肿瘤患者,在卡瑞利珠单抗联合化疗治疗3个周期后出现声音嘶哑.排外肿瘤脑转移,声带损伤等原因后考虑为药物引起的声音嘶哑.予以停用卡瑞利珠单抗后患者声音嘶哑改善.目前已有1例卡瑞利珠单抗相关声音嘶哑的报道,其他免疫检查点抑制剂(immune check-point inhibitors,ICIs)相关6例,但这些病例声音嘶哑都继发于肌病、神经病变或感染等不良反应.该文报道的患者声音嘶哑为唯一不良反应症状,并不继发于其他不良反应.
Abstract
A 67-year-old male was diagnosed with a hepa-toma.After three sessions of camrelizumab plus chemo-therapy,there was an onset of dysphonia.As brain metastases and vocal cords disease were excluded,drug-related disorder was suspected and camrelizumab dosing discontinued.At Day 60,the symptom of hoarseness disappeared.Only 1 case of camrelizumab and 6 cases of other ICIs-related dysphonia have been described so far.Our case stood out for isolated dysphonia without any other adverse reactions of myopathy and infection.
关键词
卡瑞利珠单抗/声音嘶哑/肝恶性肿瘤Key words
camrelizumab/dysphonia/liver cancer引用本文复制引用
出版年
2024
NETL
NSTL
万方数据